How to buy Cabaletta Bio stock (CABA)

Cabaletta Bio is a biotechnology business based in the US. Cabaletta Bio shares (CABA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.38 – a decrease of 15.6% over the previous week. Cabaletta Bio employs 136 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Cabaletta Bio stock

Buy Cabaletta Bio stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Cabaletta Bio stock price (NASDAQ: CABA)

Use our graph to track the performance of CABA stocks over time.

Cabaletta Bio shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$2.38
52-week range	$1.76 - $26.35
50-day moving average more info button	$3.64
200-day moving average more info button	$8.46
Wall St. target price	$22.10
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.16

Is it a good time to buy Cabaletta Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cabaletta Bio price performance over time

Historical closes compared with the close of $2.38 from 2024-12-20

1 week (2024-12-16)	-12.18%
1 month (2024-11-22)	27.27%
3 months (2024-09-23)	-45.54%
6 months (2024-06-21)	-71.93%

1 year (2023-12-22)	-89.25%
2 years (2022-12-23)	-71.93%
3 years (2021-12-23)	4.24
5 years (2019-12-23)	13.56

Cabaletta Bio financials

Gross profit TTM	$0
Return on assets TTM	-31.13%
Return on equity TTM	-48.16%
Profit margin	0%
Book value	$4.94
Market Capitalization more info button	$111.9 million

TTM: trailing 12 months

Cabaletta Bio share dividends

We're not expecting Cabaletta Bio to pay a dividend over the next 12 months.

Cabaletta Bio share price volatility

Over the last 12 months, Cabaletta Bio's shares have ranged in value from as little as $1.76 up to $26.35. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cabaletta Bio's is 2.419. This would suggest that Cabaletta Bio's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Cabaletta Bio overview

Cabaletta Bio, Inc. , a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co. , Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc.

Frequently asked questions

null
What percentage of Cabaletta Bio is owned by insiders or institutions?
Currently 3.099% of Cabaletta Bio shares are held by insiders and 100.467% by institutions. How many people work for Cabaletta Bio?
Latest data suggests 136 work at Cabaletta Bio. When does the fiscal year end for Cabaletta Bio?
Cabaletta Bio's fiscal year ends in December. Where is Cabaletta Bio based?
Cabaletta Bio's address is: 2929 Arch Street, Philadelphia, PA, United States, 19104 What is Cabaletta Bio's ISIN number?
Cabaletta Bio's international securities identification number is: US12674W1099 What is Cabaletta Bio's CUSIP number?
Cabaletta Bio's Committee on Uniform Securities Identification Procedures number is: 12674W109